-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$18.671370.08% Upside
Taysha Gene Therapies, Inc. Frequently Asked Questions
-
What analysts cover Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. has been rated by research analysts at BMO Capital, Piper Sandler, Jefferies, Raymond James, Morgan Stanley, Cantor Fitzgerald in the past 90 days.